You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-low

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DESTINY Breast Respond HER2-low Europe

Not yet recruiting
  • Unresectable Breast Cancer
  • +2 more
  • Trastuzumab deruxtecan
  • (no location specified)
Jul 6, 2023

Survival Rate of HER2-Low Breast Cancer Patients

Completed
  • HER2 Low Breast Carcinoma
  • immunohistochemistry (IHC) and in situ hybridization (ISH) Test
  • (no location specified)
Mar 2, 2023

HER2-low in Metastatic Breast Cancer Patients

Not yet recruiting
  • HER2-negative
    • (no location specified)
    Nov 9, 2023

    Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

    Recruiting
    • Gastric Cancer
    • HER2-low-expressing Gastric Cancer
    • Shanghai, China
      Shanghai East Hospital
    Oct 9, 2023

    Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

    Active, not recruiting
    • Hormone-receptor-positive Breast Cancer
    • +2 more
    • No drug
    • Cambridge, Massachusetts
      ConcertAI database
    Sep 8, 2023

    Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

    Not yet recruiting
    • Stomach Neoplasm
    • (no location specified)
    Oct 16, 2023

    HER2-low in Unresectable and/or Metastatic Breast Cancer

    Not yet recruiting
    • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
      • (no location specified)
      Nov 6, 2023

      HER2-low Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      Advanced Breast Cancer Trial (Disitamab vedotin)

      Not yet recruiting
      • Advanced Breast Cancer
      • Disitamab vedotin
      • (no location specified)
      Apr 16, 2023

      Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

      Not yet recruiting
      • Breast Cancer Invasive
      • +3 more
      • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
      • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
      • Guangzhou, Guangdong, China
        Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      Nov 17, 2023

      Breast Cancer Trial (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • (no location specified)
      Jul 10, 2023

      Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

      Not yet recruiting
      • Breast Cancer
      • Disitamab Vedotin+Anlotinib
      • (no location specified)
      Aug 14, 2023

      HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

      Not yet recruiting
      • HER2 Low Breast Carcinoma
      • SHR-A1811 for injection
      • (no location specified)
      Jun 12, 2023

      HER2 Low Advanced or Metastatic Breast Cancer Trial (SHR-A1811 & Dalpiciclib Isethionate Tablets, SHR-A1811 & Fulvestrant,

      Not yet recruiting
      • HER2 Low Advanced or Metastatic Breast Cancer
      • SHR-A1811 & Dalpiciclib Isethionate Tablets
      • +2 more
      • (no location specified)
      Mar 19, 2023

      HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

      Recruiting
      • HR Positive/HER2 Low Expression Metastatic Breast Cancer
      • Disitamab vedotin
      • Endocrine therapy
      • Guangzhou, Guangdong, China
      • +2 more
      Jun 19, 2023

      Breast Cancer, Metastatic Breast Cancer Trial (Trastuzumab-Deruxtecan (T-DXd))

      Not yet recruiting
      • Breast Cancer
      • Metastatic Breast Cancer
      • Trastuzumab-Deruxtecan (T-DXd)
      • (no location specified)
      Sep 20, 2023

      Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab

      Not yet recruiting
      • Invasive Breast Cancer
      • +4 more
      • Boston, Massachusetts
      • +1 more
      Mar 20, 2023

      Breast Cancer Trial in Houston (Trastuzumab deruxtecan, Valemetostat)

      Not yet recruiting
      • Breast Cancer
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 14, 2022

      Breast Cancer Trial in Chengdu (Disitamab Vedotin, Penpulimab)

      Not yet recruiting
      • Breast Cancer
      • Chengdu, Chengdu, Sichuan, China, China
        West China Hospital, Sichuan University
      Feb 9, 2023

      Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

      Not yet recruiting
      • Breast Neoplasms
      • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
      • +2 more
      Oct 23, 2023

      Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

      Not yet recruiting
      • Breast Cancer
      • Tianjin, China
        Tianjin Cancer Hospital
      Mar 28, 2023

      Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)

      Not yet recruiting
      • Gastric Cancer
      • Gastroesophageal Junction (GEJ) Cancer
      • T-Dxd(Trastuzmab deruxtecan), Ramucirumab
      • (no location specified)
      Jun 7, 2023

      Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Triple-Negative Breast Cancer
      • Trastuzumab Deruxtecan
      • Shanghai, Shanghai, China
        Breast cancer institute of Fudan University Cancer Hospital
      Jul 12, 2023

      Breast Cancer Trial (SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel)

      Not yet recruiting
      • Breast Cancer
      • (no location specified)
      Apr 3, 2023

      HER2 Low and Describe SoC, Treatment Patterns, and Outcome in

      Completed
      • Breast Cancer
      • None (Observational study)
      • Pittsburgh, Pennsylvania
      • +12 more
      May 25, 2022